Gastrointestinal · PANCE / PANRE

Peptic Ulcer Disease (PUD)

Mucosal break >5 mm in the stomach or duodenum, most often due to H. pylori or NSAIDs.

Also known as: PUD, peptic ulcer, gastric ulcer, duodenal ulcer

Overview

Mucosal defect of the stomach or duodenum extending through the muscularis mucosae, typically ≥5 mm in diameter. Caused by an imbalance between mucosal aggressors (acid, pepsin, H. pylori, NSAIDs) and protective factors (mucus, bicarbonate, prostaglandins, blood flow).

Epidemiology

Lifetime prevalence 5-10%. Duodenal ulcers outnumber gastric ulcers ~4:1 historically, declining with H. pylori eradication. Incidence falling in developed countries; NSAID-related ulcers rising in elderly.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Peptic Ulcer Disease (PUD) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Helicobacter pylori infection (responsible for ~70% of duodenal and ~40% of gastric ulcers)
  • NSAID and aspirin use (dose-dependent; risk amplified in elderly, prior ulcer, concurrent steroid or anticoagulant)
  • Smoking, heavy alcohol use
  • Physiologic stress (ICU, mechanical ventilation >48 h, burns — Curling ulcer; head injury — Cushing ulcer)
  • Zollinger-Ellison syndrome (gastrinoma) — multiple ulcers, refractory, distal duodenum/jejunum
  • Chronic kidney disease, cirrhosis, COPD
  • Glucocorticoids — risk amplifier when combined with NSAIDs (independent risk weak)

Pathophysiology

H. pylori produces urease, ammonia, cytotoxin-associated antigen (CagA), and vacuolating toxin (VacA), inducing chronic gastritis. Antral-predominant infection increases acid secretion → duodenal ulcer. Corpus-predominant atrophic gastritis decreases acid → gastric ulcer and cancer risk. NSAIDs inhibit COX-1, reducing prostaglandin-mediated mucus, bicarbonate, and mucosal blood flow.

Clinical presentation

Symptoms

  • Epigastric pain — burning, gnawing, or hunger-like
  • Duodenal ulcer: pain 2-3 h after meals, relieved by food or antacids, nocturnal awakening
  • Gastric ulcer: pain worsened by food, weight loss
  • Nausea, early satiety, bloating, belching
  • Hematemesis, melena, or hematochezia if bleeding

Signs / physical exam

  • Epigastric tenderness on palpation
  • Signs of GI bleeding: pallor, tachycardia, orthostasis
  • Peritoneal signs (rigid abdomen, rebound) if perforated — surgical emergency
  • Succussion splash if gastric outlet obstruction

Classic findings

Duodenal: pain relieved by eating. Gastric: pain provoked by eating.

Differential diagnosis

  • GERD — Retrosternal burning rather than epigastric pain; relieved by antacids; normal mucosa or esophagitis on EGD
  • Functional dyspepsia — Symptoms identical to PUD but normal EGD; Rome IV criteria; treat with PPI ± prokinetic
  • Gastric cancer — Weight loss, anemia, persistent ulcer despite therapy, age >55; biopsy all gastric ulcers
  • Acute pancreatitis — Epigastric pain radiating to back, lipase >3× ULN; alcohol or gallstones
  • Cholelithiasis / biliary colic — RUQ or epigastric pain after fatty meals, lasting hours; gallstones on ultrasound
  • Mesenteric ischemia — Postprandial pain out of proportion, weight loss, atherosclerotic risk factors; CT angiography
  • Acute coronary syndrome (inferior MI) — Epigastric pain with diaphoresis, dyspnea; ECG and troponin in older patients or with cardiac risk factors
  • Zollinger-Ellison syndrome — Multiple, refractory, or distal ulcers; diarrhea; fasting gastrin >1000 pg/mL with elevated gastric pH

Diagnostic workup

Labs

  • CBC (anemia from chronic blood loss)
  • BMP, LFTs
  • Type and screen / crossmatch if acute bleed
  • H. pylori testing: urea breath test or stool antigen (preferred non-invasive); biopsy-based rapid urease test or histology if EGD performed
  • Fasting gastrin level if Zollinger-Ellison suspected

Imaging

  • Upper endoscopy (EGD) — gold standard; visualizes ulcer, allows biopsy and therapeutic intervention; biopsy ALL gastric ulcers to exclude malignancy
  • Upright CXR — free air under diaphragm in perforation
  • CT abdomen with contrast if perforation or complication suspected

Other studies

  • Withhold PPI 2 weeks and antibiotics 4 weeks before H. pylori testing to avoid false negatives
  • Repeat EGD in 8-12 weeks to confirm gastric ulcer healing and re-biopsy if not healed

Diagnostic algorithm

FeatureDuodenal UlcerGastric Ulcer
Pain timing2-3 h after meals, nocturnalSoon after eating
Effect of foodRelievedWorsened
Typical age30-5555-70
Acid secretionIncreased or normalNormal or decreased
H. pylori prevalence~70%~40%
Malignancy riskNegligible4% — biopsy all
Bleeding riskHigher (posterior — gastroduodenal artery)Lower
Repeat EGDNot routine8-12 weeks to confirm healing
Duodenal vs gastric ulcer — distinguishing features.

Treatment

First-line

  • PPI — omeprazole, pantoprazole, esomeprazole — 4-8 weeks (8-12 weeks for gastric ulcer)
  • H. pylori eradication if positive (see by_subtype)
  • Discontinue NSAIDs and aspirin if possible; switch to acetaminophen
  • Lifestyle: smoking cessation, limit alcohol

H. pylori positive — first-line if local clarithromycin resistance <15%

  • Bismuth quadruple therapy (PREFERRED in most US regions): PPI BID + bismuth subsalicylate QID + tetracycline QID + metronidazole QID × 14 days
  • Or clarithromycin triple therapy: PPI BID + clarithromycin BID + amoxicillin BID (or metronidazole if PCN-allergic) × 14 days — only if no prior macrolide exposure and local resistance low

H. pylori — second-line / salvage

  • Levofloxacin triple: PPI BID + levofloxacin daily + amoxicillin BID × 14 days
  • Rifabutin triple (PPI + rifabutin + amoxicillin) for refractory cases
  • Confirm eradication 4 weeks after therapy with urea breath test or stool antigen

NSAID-induced

  • Stop NSAID; if continuation necessary, use lowest dose plus PPI co-therapy
  • Misoprostol QID as alternative gastroprotective agent (contraindicated in pregnancy)
  • Consider COX-2 selective inhibitor (celecoxib) with PPI in high-risk patients balanced against CV risk

Bleeding ulcer (Forrest classification)

  • IV PPI bolus + infusion (or intermittent high-dose IV PPI)
  • Endoscopic hemostasis for active bleeding, visible vessel, or adherent clot (combination injection plus thermal or clip)
  • Transfuse to Hgb ≥7 (≥8 if cardiovascular disease)
  • IR embolization or surgery if endoscopic failure

Complications

  • Upper GI bleeding (most common complication)
  • Perforation — sudden severe epigastric pain, peritonitis, free air on imaging; surgical repair (Graham patch)
  • Penetration — into pancreas, biliary tree, or adjacent organ
  • Gastric outlet obstruction — early satiety, vomiting of undigested food, succussion splash
  • Gastric malignancy — especially long-standing H. pylori; MALT lymphoma can regress with eradication

PANCE pearls

  • Biopsy ALL gastric ulcers — 4% harbor malignancy; duodenal ulcers virtually never malignant.
  • Confirm H. pylori eradication 4 weeks post-treatment in all patients (especially complicated PUD, MALT lymphoma, refractory dyspepsia).
  • Withhold PPI 2 weeks before urea breath test or stool antigen; serology unaffected but cannot confirm active infection.
  • Forrest IIc (flat pigmented spot) and III (clean base) do not require endoscopic therapy — early PPI and feeding.
  • Recurrent or refractory ulcer, multiple ulcers, or ulcers distal to duodenal bulb — check fasting gastrin for Zollinger-Ellison.
  • Curling ulcer (burn patient) and Cushing ulcer (head injury) are stress ulcers — prophylax high-risk ICU patients with PPI or H2RA.

References

  • ACG 2017 — Chey WD et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017;112:212-239
  • ACG 2021 — Laine L et al. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding. Am J Gastroenterol 2021;116:899-917
  • Maastricht VI/Florence — Malfertheiner P et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence Consensus Report. Gut 2022;71:1724-1762

Practice Gastrointestinal questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.